Nurexone Biologic Inc NRX
TSXV · Canada · Health Technology
CAD 0.64000.00 (0.00%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in BostonTORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a series of U.S. engagements across four major life sciences events taking place in Boston from September 2
Shareholders grant the Board discretionary authority to implement a share consolidation of up to 30:1TORONTO and HAIFA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, September 15, 202
Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar marketsTORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces that its Israeli subsidiary, NurExone Biologic Ltd., has entered into a Memorandum of Understanding (the “MOU”) with NanoPa
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.